



Poster Numbers

Poster Number	Day	First Name	Last Name	Organization	Country	Poster Title	Theme
P01	Wed 18 Sept	Ashley	Benson	University Of Utah	United States	Low frequency of antiphospholipid antibodies in women with recurrent embryonic and pre-embryonic losses.	(01) Diagnostics: criteria and non-criteria laboratory tests
P02	Wed 18 Sept	Ashley	Benson	University Of Utah	United States	Phosphatidylserine-dependent antiprothrombin antibodies may identify patients who are negative for classic antiphospholipid antibodies.	(01) Diagnostics: criteria and non-criteria laboratory tests
P03	Wed 18 Sept	Daniel	Pleguezuelo	Hospital Universitario 12 De Octubre	Spain	Redefining the cutoff for ALBIA technique in antiphospholipid syndrome	(01) Diagnostics: criteria and non-criteria laboratory tests
P04	Wed 18 Sept	Daniel	Pleguezuelo	Hospital Universitario 12 De Octubre	Spain	Diagnostic performance for APS laboratory-criteria in 40 different laboratories.	(01) Diagnostics: criteria and non-criteria laboratory tests
P05	Wed 18 Sept	Silvia	Casas	Inova Diagnostics	Spain	Consecutive testing of anti-Phosphatidylserine/Prothrombin IgG and IgM antibodies further improves Anti-Phospholipid Syndrome clinical assessment	(01) Diagnostics: criteria and non-criteria laboratory tests
P06	Wed 18 Sept	Jean	Devignes	Chru De Nancy	France	Extended persistence of antiphospholipid antibodies beyond confirmation at twelve weeks	(01) Diagnostics: criteria and non-criteria laboratory tests
P07	Wed 18 Sept	Katrien	Devreese	Ghent University Hospital	Belgium	Evaluation of the effect of unfractionated heparin, enoxaparin and danaparoid on lupus anticoagulant testing	(01) Diagnostics: criteria and non-criteria laboratory tests
P08	Wed 18 Sept	Katrien	Devreese	Ghent University Hospital	Belgium	Evaluation of DOAC-Stop® for the elimination of the effect of DOAC on lupus anticoagulant testing	(01) Diagnostics: criteria and non-criteria laboratory tests
P09	Wed 18 Sept	Colin	Douglas	Precision Biologic	Canada	Effects of Common Interferents in Hexagonal Phase Phospholipid Neutralization Testing	(01) Diagnostics: criteria and non-criteria laboratory tests
P10	Wed 18 Sept	Maria	Efthymiou	University College London	United Kingdom	Protein C antibodies and acquired activated protein C resistance in systemic lupus erythematosus	(01) Diagnostics: criteria and non-criteria laboratory tests
P11	Wed 18 Sept	Sahwa	Elbagir	Uppsala University	Sweden	Increased IgA cardiolipin and IgA b2GPI levels and prevalence among apparently healthy pregnant Sudanese Women	(01) Diagnostics: criteria and non-criteria laboratory tests
P12	Wed 18 Sept	Arvind	Ganapati	Christian Medical College Hospital, Vellore, India	India	Clinical utility of Antibodies to C1q sub-component as a biomarker of Anti-phospholipid syndrome	(01) Diagnostics: criteria and non-criteria laboratory tests
P13	Wed 18 Sept	Soad	Haj yahia	Sheba Medical Center	Israel	Clinical Implications, Morbidity and Mortality In patients with positive antiphospholipid antibodies tests during hospitalization	(01) Diagnostics: criteria and non-criteria laboratory tests
P14	Wed 18 Sept	Tingting	Liu	Department Of Rheumatology And Immunology, Ruijin Hospital, Shanghai Jiao Tong University School Of Medicine	China	Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and pregnancy loss in APS patients	(01) Diagnostics: criteria and non-criteria laboratory tests
P15	Wed 18 Sept	Thomas	McDonnell	University College London	United Kingdom	An Acid Free Purification Protocol for Purification of Beta-2-Glycoprotein I from Patient Serum	(01) Diagnostics: criteria and non-criteria laboratory tests
P16	Wed 18 Sept	Laura	Naranjo	Hospital Universitario 12 De Octubre	Spain	The presence of Immune-complexes of IgG/IgM bound to B2-glycoprotein-I is associated with extra-criteria APS manifestations	(01) Diagnostics: criteria and non-criteria laboratory tests
P17	Wed 18 Sept	Michelle	Petri	Johns Hopkins University School Of Medicine	United States	Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis	(01) Diagnostics: criteria and non-criteria laboratory tests
P18	Wed 18 Sept	Michelle	Petri	Johns Hopkins University School Of Medicine	United States	Persistency In Platelet C4d And Thrombosis Risk Score Associate With Thrombosis In Systemic Lupus Erythematosus	(01) Diagnostics: criteria and non-criteria laboratory tests
P19	Wed 18 Sept	Massimo	Radin	University Of Turin	Italy	Anti-phosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome	(01) Diagnostics: criteria and non-criteria laboratory tests
P20	Wed 18 Sept	Carlos	Ramirez	Inova Diagnostics	United States	Evaluation of a Novel Multi-Analyte Assay in the Diagnosis of APS in a Swedish Cohort	(01) Diagnostics: criteria and non-criteria laboratory tests
P21	Wed 18 Sept	Andrea	Seaman	Inova Diagnostics	United States	Enhanced Clinical Performance of anti-Phosphatidylserine/Prothrombin Complex in Comparison to anti-Phosphatidylserine in the Diagnosis of APS	(01) Diagnostics: criteria and non-criteria laboratory tests
P22	Wed 18 Sept	Antonio	Serrano	Healthcare Research Institute of Hospital "12 de Octubre"	Spain	Inclusion of anti-B2GPI-IgA and anti-Phosphatidylserine/Prothrombin in the classification criteria would double the diagnoses of APS.	(01) Diagnostics: criteria and non-criteria laboratory tests
P23	Wed 18 Sept	Manuel	Serrano	Hospital Clinico San Carlos	Spain	Beta-2 glycoprotein-1 domains 3 and 4 contains antigenic zones for IgA and classic antiphospholipid antibodies	(01) Diagnostics: criteria and non-criteria laboratory tests
P24	Wed 18 Sept	Flavio	Signorelli	Universidade Estadual Do Rio De Janeiro	Brazil	Thrombocytopenia is highly associated with specific antiphospholipid antibodies profiles.	(01) Diagnostics: criteria and non-criteria laboratory tests
P25	Wed 18 Sept	Christopher	Sjöwall	Linköping University	Sweden	Galectin-9 as a surrogate biomarker for IFNα in systemic lupus erythematosus with and without APS	(01) Diagnostics: criteria and non-criteria laboratory tests
P26	Wed 18 Sept	Liyan	Wan	Rui Jin Hospital Shanghai Jiao Tong University School Of Medicine	China	The clinical performance of fully automated chemiluminescent antiphospholipid antibody assays in diagnosing antiphospholipid syndrome.	(01) Diagnostics: criteria and non-criteria laboratory tests
P27	Wed 18 Sept	Polona	Zigon	University Medical Centre	Slovenia	Non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome	(01) Diagnostics: criteria and non-criteria laboratory tests
P28	Wed 18 Sept	Daniel	Pleguezuelo	Hospital Universitario 12 De Octubre	Spain	IgA Anti-β2glycoprotein-I antibodies are the main risk factor in asymptomatic-carriers to suffer an APS event	(02) Classification Criteria

P29	Wed 18 Sept	Daniel	Pleguezuelo	Hospital Universitario 12 De Octubre	Spain	IgA anti-β2-Glycoprotein-I isolated positivity and APS:Studies published in the last 5 years support its relevance	(02) Classification Criteria
P30	Wed 18 Sept	Savino	Sciascia	Center Of Research Of Immunopathology And Rare Diseases, University Of Torino, It	Italy	Identifying phenotypes of patients with Antiphospholipid Antibodies: results from a cluster analysis	(02) Classification Criteria
P31	Wed 18 Sept	Jiuliang	Zhao	Peking Union Medical College Hospital	China	Antiphospholipid Antibodies Associated Non-criteria Clinical Manifestations Should Not Be Ignored	(02) Classification Criteria
P32	Thurs 19 Sept	Ali	Duarte	Mayo Clinic	United States	Epidemiology of the Antiphospholipid Syndrome. A Population-Based Study	(03) Basic Science: Aetiology including epidemiology
P33	Thurs 19 Sept	Sarah	Dyball	University Of Manchester	United Kingdom	Not Just Lupus - Antiphospholipid Syndrome in Connective Tissue Diseases: Results from the LEAP Study	(03) Basic Science: Aetiology including epidemiology
P34	Thurs 19 Sept	Cecilia	Nalli	Unit Of Rheumatology And Clinical Immunology, Spedali Civili Of Brescia	Italy	Epidemiology of vascular Primary Antiphospholipid Syndrome	(03) Basic Science: Aetiology including epidemiology
P35	Thurs 19 Sept	Jose	Pardos-Gea	Systemic Autoimmune Diseases Unit. Vall d'Hebrón University Hospital	Spain	Survival in APS depending on diagnostic decade:analysis of a cohort of 100 patients since 1980.	(03) Basic Science: Aetiology including epidemiology
P36	Thurs 19 Sept	Tatiana	Pires	Centro Hospitalar De Leiria	Portugal	Secondary APS and Thrombocytopenia in SLE - a Cohort Analysis	(03) Basic Science: Aetiology including epidemiology
P37	Thurs 19 Sept	My Nhi	Dang	Imperial College London	United Kingdom	Plasma Von Willebrand Factor (VWF) and ADAMTS13 profiles in Antiphospholipid Syndrome and Systemic Lupus Erythematosus	(04) Basic Science and pathogenesis
P38	Thurs 19 Sept	Yann	Becker	Centre De Recherche Du Chu De Québec - Université Laval	Canada	Antibodies targeting mitochondrial antigens are associated with reduced thrombotic events in the antiphospholipid syndrome (APS).	(04) Basic Science and pathogenesis
P39	Thurs 19 Sept	Thomas	McDonnell	University College London	United Kingdom	Studying The Structure and Function of Plasmin Clipped Beta-2-Glycoprotein-1: The Saga Begins.	(04) Basic Science and pathogenesis
P40	Thurs 19 Sept	Naoki	Ohnishi	Department Of Rheumatology, Endocrinology And Nephrology, Faculty Of Medicine And Graduate School Of Medicine, Hokkaido	Japan	Prothrombin/MHC class II complexes on procoagulant cells are novel immune target for pathogenic antiphospholipid antibodies	(04) Basic Science and pathogenesis
P41	Thurs 19 Sept	Fernanda	Orsi	University of Campinas (UNICAMP)	Brazil	Neutrophil Activity in Patients with Antiphospholipid Syndrome.	(04) Basic Science and pathogenesis
P42	Thurs 19 Sept	Vittorio	Pengo	University Of Padua	Italy	Circulating platelet microparticles in different antiphospholipid antibody profiles	(04) Basic Science and pathogenesis
P43	Thurs 19 Sept	Vittorio	Pengo	University Of Padua	Italy	Effect of purified anti β2-Glycoprotein I from triple positive APS patients on thrombin generation	(04) Basic Science and pathogenesis
P44	Thurs 19 Sept	Vittorio	Pengo	University Of Padua	Italy	Effect of affinity purified anti-β2-Glycoprotein I antibodies on diluted prothrombin time: importance of reagents sequence	(04) Basic Science and pathogenesis
P45	Thurs 19 Sept	Natalie	Sippl	Karolinska Institutet	Sweden	Domain specific anti-β2GPI antibodies in patients with First Myocardial Infarction	(04) Basic Science and pathogenesis
P46	Thurs 19 Sept	Rohan	Willis	Antiphospholipid Standardization Laboratory, University Of Texas Medical Branch	United States	Comparative Efficacy of B2GPI Domain V Structural Analogue Variants in Preventing APL-Mediated EC Activation	(04) Basic Science and pathogenesis
P47	Thurs 19 Sept	Rohan	Willis	Antiphospholipid Standardization Laboratory, University Of Texas Medical Branch	United States	Inhibition of IκB kinase(IKK) Complex of Canonical NF-κB Pathway in APL-Mediated EC Activation	(04) Basic Science and pathogenesis
P48	Thurs 19 Sept	Silvia Grazietta	Foddai	San Giovanni Bosco Hospital, Univesity of Turin	Italy	aPL prevalence in women with late pregnancy complication and low-risk for chromosomal abnormalities	(05) Basic Science: placental / pregnancy morbidity
P49	Thurs 19 Sept	Arzu	Soybilgic	Univ Of Illinois At Chicago	United States	Utility of Cardiac Stress MRI in the Diagnosis of Cardiac Microvascular Disease in Antiphospholipid Syndrome	(06) Diagnostics: imaging and other modalities
P50	Thurs 19 Sept	Giulia	Ferrannini	Karolinska Intitutet	Italy	Dysglycaemic patients with antiphospholipid antibodies IgG: a neglected group at high cardiovascular risk?	(07) Thrombotic disease: arterial thromboembolism / atherosclerosis
P51	Thurs 19 Sept	Soad	Haj yahia	Sheba Medical Center	Israel	Chronic Thromboembolic Pulmonary Hypertension in Patients with Antiphospholipid Syndrome: Risk Factors and Management	(07) Thrombotic disease: arterial thromboembolism / atherosclerosis
P52	Thurs 19 Sept	Raquel	Diaz	Hospital 12 De Octubre	Spain	aPL screening in diagnosis of first venous thromboembolic event would identify SAF in 30%	(08) Thrombotic disease: venous thromboembolism
P53	Thurs 19 Sept	Susanna	Nallamilli	University College Hospital London	United Kingdom	Antiphospholipid syndrome and myeloproliferative neoplasm: A systematic review and case series	(08) Thrombotic disease: venous thromboembolism
P54	Thurs 19 Sept	Jiuliang	Zhao	Peking Union Medical College Hospital	China	Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis	(08) Thrombotic disease: venous thromboembolism
P55	Thurs 19 Sept	Laura	Naranjo	Hospital Universitario 12 De Octubre	Spain	Antiphospholipid syndrome behind ischemic strokes	(09) Thrombotic disease: cerebral APS
P56	Thurs 19 Sept	Maria	Altman	Karolinska University Hospital	Sweden	APS association to SLE in children and adolescents, a case series	(10) Paediatric APS
P57	Thurs 19 Sept	Elizabeth	Sloan	University Of Texas Southwestern	United States	Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers	(10) Paediatric APS
P58	Thurs 19 Sept	Kuniyuki	Asou	Department Of Rheumatology, Endocrinology And Nephrology, Faculty Of Medicine And Graduate School Of Medicine, Hokkaido	Japan	Discrimination of intracranial vasculitis from thrombotic antiphospholipid syndrome in lupus patients with antiphospholipid antibodies	(11) Case Reports

P59	Thurs 19 Sept	Arvind	Ganapati	Christian Medical College Hospital,Vellore,India	India	Two Cases of lupus anti-coagulant hypo-prothrombinemia syndrome	(11) Case Reports
P60	Thurs 19 Sept	Jiuliang	Zhao	Peking Union Medical College Hospital	China	Hepatic Infarction Caused by Antiphospholipid Syndrome Secondary to Systemic Lupus Erythematosus	(11) Case Reports
P61	Thurs 19 Sept	Maria Francisca	Moraes-Fontes	Hospital Curry Cabral, Centro Hospitalar Universitário de Lisboa Central	Portugal	Twists and turns from antiphospholipid antibodies: how to switch them off	(11) Case Reports
P62	Thurs 19 Sept	Jamilya	Khizroeva	I.M.Sechenov First Moscow State Medical University (Sechenov University)	Russia	Neonatal thrombosis and maternal and fetal thrombophilia	(10) Paediatric APS
P63	Fri 20 Sept	Cecilia	Chighizola	Istituto Auxologico Italiano	Italy	The first pregnancy in women with positive anti-phospholipid antibodies: clues for treatment	(12) Obstetric APS
P64	Fri 20 Sept	Cecilia	Chighizola	Istituto Auxologico Italiano	Italy	A stratification algorithm predicts obstetric risk and response to treatment in women with anti-phospholipid antibodies	(12) Obstetric APS
P65	Fri 20 Sept	Guilherme	de Jesús	Universidade do Estado do Rio de Janeiro	Brazil	Recurrent early pregnancy loss is associated with higher aGAPSS in thrombotic Primary Antiphospholipid Syndrome	(12) Obstetric APS
P66	Fri 20 Sept	Guilherme	de Jesús	Universidade do Estado do Rio de Janeiro	Brazil	High frequency of preeclampsia and fetal growth restriction despite aspirin use in patients with APS	(12) Obstetric APS
P67	Fri 20 Sept	Hannah	Kither	University of Manchester	United Kingdom	Undiagnosed Lupus Like Autoimmunity and Stillbirth	(12) Obstetric APS
P68	Fri 20 Sept	Patrícia	Martins	Instituto de Medicina Molecular	Portugal	Pregnancy outcomes in antiphospholipid syndrome: 9 year-experience from a multidisciplinary unit	(12) Obstetric APS
P69	Fri 20 Sept	Agna	Neto	Hospital Egas Moniz	Portugal	Adverse pregnancy outcomes in antiphospholipid antibody carriers: results from a specialized multidisciplinary unit	(12) Obstetric APS
P70	Fri 20 Sept	Jose	Pardos-Gea	Systemic Autoimmune Diseases Unit. Vall d'Hebrón University Hospital	Spain	Safety of prophylactic LDA/LMWH during pregnancy in women with poor aPL-related obstetric outcomes	(12) Obstetric APS
P71	Fri 20 Sept	Jose	Pardos-Gea	Systemic Autoimmune Diseases Unit. Vall d'Hebrón University Hospital	Spain	Validity of shortened version Global Antiphospholipid Syndrome Score (aGAPSS) in 1.000 patients' cohort with OAPS.	(12) Obstetric APS
P72	Fri 20 Sept	Massimo	Radin	University Of Turin	Italy	Pregnancy success rate and response to heparins and/or aspirin according to the GAPSS score	(12) Obstetric APS
P73	Fri 20 Sept	Udry	Sebastian	Durand	Argentina	A high-risk laboratory profile of aPL and thrombosis are associated with extra-criteria manifestations on POAPS	(12) Obstetric APS
P74	Fri 20 Sept	Jose	Pardos-Gea	Systemic Autoimmune Diseases Unit. Vall d'Hebrón University Hospital	Spain	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A Survey of 1100 Consecutive Cases	(12) Obstetric APS
P75	Fri 20 Sept	Kenji	Tanimura	Kobe University Graduate School Of Medicine	Japan	Autoantibody against beta2-glycoprotein I/HLA class II complex as a risk factor for recurrent pregnancy loss	(12) Obstetric APS
P76	Fri 20 Sept	Angela	Tincani	University And Asst-spedali Civili Brescia Italy	Italy	Pregnancy outcome in aPL carriers: results from a multicenter Italian study over 20 years	(12) Obstetric APS
P77	Fri 20 Sept	Hiroyuki	Yoshihara	Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences	Japan	The efficacy and safety of danaparoid in patients with obstetric antiphospholipid syndrome	(12) Obstetric APS
P78	Fri 20 Sept	Volodymyr	Savytskyi	University Clinic, ONMedU, Department of propedeutics of internal diseases and therapy	Ukraine	Clinical prescription of rituximab in CAPS	(13) Catastrophic APS
P79	Fri 20 Sept	Danieli	Andrade	University of Sao Paulo	Brazil	Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in PAPS and APS related to SLE	(14) Organ manifestations and APS
P80	Fri 20 Sept	Eliezer	Cunha	University Of São Paulo	Brazil	Anorectal Disease in Patients with Antiphospholipid Syndrome	(14) Organ manifestations and APS
P81	Fri 20 Sept	Raquel	Faria	Ch Universitario Do Porto	Portugal	Antiphospholipid Syndrome Clinical and Immunological Features in a Monocentric Portuguese Cohort	(14) Organ manifestations and APS
P82	Fri 20 Sept	Raquel	Faria	Ch Universitario Do Porto	Portugal	The role of Multiple Autoimmune Syndrome in APS clinical, genetic and immunological features	(14) Organ manifestations and APS
P83	Fri 20 Sept	Jose María	Pego Reigosa	Complejo Hospitalario Vigo	Spain	Do all antiphospholipid antibodies confer the same risk for major organ involvement in SLE patients?	(14) Organ manifestations and APS
P84	Fri 20 Sept	Daphna	Paran	Tel-aviv Medical Center	Israel	The efficacy of Rituximab for refractory manifestations of the antiphospholipid syndrome – an Israeli experience	(15) Therapeutic Aspects
P85	Fri 20 Sept	Rebecca	De Lorenzo	Vita-Salute San Raffaele University	Italy	Heparin and aspirin efficacy in pregnant patients with recurrent idiopathic miscarriage independent of antiphospholipid syndrome	(15) Therapeutic Aspects
P86	Fri 20 Sept	Fernanda	Orsi	University of Campinas (UNICAMP)	Brazil	Changes in inflammation and coagulation in patients with thrombotic primary antiphospholipid syndrome treated with hydroxychloroquine	(15) Therapeutic Aspects
P87	Fri 20 Sept	Fernanda	Orsi	University of Campinas (UNICAMP)	Brazil	Hydroxychloroquine use affects immunological and lipid profiles in patients with thrombotic primary antiphospholipid syndrome	(15) Therapeutic Aspects
P88	Fri 20 Sept	Michelle	Petri	Johns Hopkins University School Of Medicine	United States	Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematosus	(15) Therapeutic Aspects
P89	Fri 20 Sept	Michelle	Petri	Johns Hopkins University School Of Medicine	United States	Effect of Treatment on Antiphospholipid Antibodies in SLE	(15) Therapeutic Aspects

P90	Fri 20 Sept	Taiki	Sato	Hokkaido University	Japan	Longitudinal efficacy and safety of direct factor Xa inhibitors in patients with antiphospholipid syndrome	(15) Therapeutic Aspects
P91	Fri 20 Sept	Udry	Sebastian	Durand	Argentina	Hydroxychloroquine for the prevention of relapses in 812 patients with primary antiphospholipid syndrome	(15) Therapeutic Aspects
P92	Fri 20 Sept	Antonio	Serrano	Healthcare Research Institute of Hospital "12 de Octubre"	Spain	Resetting humoral immunity by targeting plasma cells as a new Antiphospholipid Syndrome therapy	(15) Therapeutic Aspects
P93	Fri 20 Sept	Stéphane	Zuily	Nancy Academic Hospital	France	Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review and Meta-Analysis	(15) Therapeutic Aspects
P94	Fri 20 Sept	Stéphane	Zuily	Nancy Academic Hospital	France	Health-Related Quality of Life Impairment in Antiphospholipid Syndrome	(16) Patient Engagement and Education
P95	Fri 20 Sept	Jose	Pardos-Gea	Systemic Autoimmune Diseases Unit. Vall d'Hebrón University Hospital	Spain	Treatment of refractory poor APL-related obstetric outcomes with TNF-ALPHA blockers: results of 18 patients	(12) Obstetric APS